Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinlarebant in Stargardt Disease (DRAGON II)
NCT06388083Phase 3Active, not recruiting
- Sponsor
- Belite Bio, Inc
- Start
- Jul 2024
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of tinlarebant, sponsored by Belite Bio, Inc. Started Jul 2024; status: active, not recruiting.
02
Drugs
tinlarebant
Beyond the preview
Go deeper on NCT06388083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388083.